• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aligos Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update

    6/26/25 4:09:54 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALGS alert in real time by email
    8-K
    false 0001799448 --12-31 0001799448 2025-06-25 2025-06-25
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 25, 2025

     

     

    Aligos Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39617   82-4724808

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification Number)

     

    One Corporate Dr., 2nd Floor

    South San Francisco, CA

      94080
    (Address of principal executive offices)   (Zip Code)

    (800) 466-6059

    (Registrant’s telephone number, including area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol

     

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share   ALGS  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 25, 2025, Aligos Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). As further described in Item 5.07 of this Current Report on Form 8-K, at the Annual Meeting, the Company’s stockholders approved an amendment (the “2020 Plan Amendment”) to the Company’s 2020 Incentive Award Plan (the “2020 Plan”). The 2020 Plan Amendment was approved by the Board of Directors (the “Board”) on April 11, 2025 and became effective upon stockholder approval at the Annual Meeting.

    The 2020 Plan Amendment amends the 2020 Plan (as amended, the “Amended Plan”) to increase the number of shares reserved and scheduled to be reserved under the 2020 Plan by 1,000,000 shares, such that the number of shares reserved for issuance under the 2020 Plan will equal an aggregate of the sum of (i) 177,072 shares of common stock; (ii) any shares of common stock that were subject to awards outstanding under the 2018 Equity Incentive Plan as of October 14, 2020 that become available for issuance under the 2020 Plan pursuant to Article V of the 2020 Plan; (iii) an annual increase on the first day of each calendar year beginning in 2021 and ending in 2030, equal to the lesser of (A) 5% of the shares of common stock outstanding or, commencing January 1, 2025, issuable upon exercise of outstanding pre-funded warrants with an exercise price per share equal to one penny or less, in each case, on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of common stock as determined by the Board; and (iv) 1,000,000 shares of common stock.

    The terms and conditions of the Amended Plan are described in the section entitled “Proposal 3 – Approval of Amendment to our 2020 Incentive Award Plan” included in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2025 (the “Proxy Statement”). This description is incorporated by reference into Item 5.02 of this Current Report on Form 8-K.

    The above and the incorporated descriptions of the Amended Plan are qualified in their entirety by reference to the 2020 Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 20,000,000 shares to 100,000,000 shares and to increase the number of authorized shares of non-voting common stock from 800,000 shares to 15,800,000 shares. The increase in the number of authorized shares voting common stock and non-voting common stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 25, 2025 and was effective as of such date.

    The above description is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the Proxy Statement. Only stockholders of record as of the close of business on April 28, 2025, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 5,314,801 shares of the Company’s voting common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

    Proposal 1. The election of three Class II directors to hold office until the 2028 annual meeting of stockholders or until their respective successor is elected. The results of the vote were as follows:

     

    Nominee

       Votes For      Votes Withheld      Broker
    Non-Votes
     

    K. Peter Hirth, Ph.D.

         2,161,021        7,106        1,268,587  

    Heather Preston, M.D.

         2,161,429        6,698        1,268,587  

    Margarita Chavez

         2,161,423        6,704        1,268,587  

     


    Proposal 2. The ratification of the selection by the audit committee of the Board of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025. The results of the vote were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

    3,429,953   4,968   1,793

    As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

    Proposal 3. The approval of an amendment to the 2020 Plan to increase the number of shares reserved and scheduled to be reserved under the 2020 Plan by 1,000,000 shares. The results of the vote were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker

    Non-Votes

    1,928,200   238,399   1,528   1,268,587

    Proposal 4. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 20,000,000 shares to 100,000,000 shares. The results of the vote were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

    2,938,972   392,536   105,206

    As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

    Proposal 5. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of non-voting common stock from 800,000 shares to 15,800,000 shares. The results of the vote were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

    2,920,916   410,528   105,270

    As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    3.1    Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aligos Therapeutics, Inc.
    10.1    Amendment to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        ALIGOS THERAPEUTICS, INC.
    Date: June 26, 2025     By:  

    /s/ Lesley Ann Calhoun

          Lesley Ann Calhoun
          Executive Vice President, Chief Operating Officer and Chief Financial Officer
    Get the next $ALGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALGS

    DatePrice TargetRatingAnalyst
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    3/11/2022$47.00 → $15.00Overweight
    Piper Sandler
    3/11/2022$10.00 → $11.00Outperform
    SVB Leerink
    2/16/2022$15.00 → $10.00Outperform
    SVB Leerink
    1/7/2022$30.00 → $12.00Overweight → Neutral
    JP Morgan
    More analyst ratings